News in brief

Rechipharm contracted to make lidocaine formulation for IUD-related pain

Rechipharm contracted to make novel lidocaine formulation

Recipharm AB will manufacture commercial supplies of a topical formulation of the anaesthetic lidocaine called Shact that is soon to be launched by developer Pharmanest AB.

The new contract –terms of which were not disclosed – will see the Swedish contract manufacturing organisation’s (CMO) semi-solid products unit make Shact – which is used to alleviate discomfort and pain during IUD insertion - at its facility in Karlskoga.

Recipharm will manufacture Shact along with a proprietary application device developed to simplify topical application in the cervix and uterus in a long term deal that will extend to any country in which the drug is launched.

The manufacturing contract is the first Recipharm has announced since it completed its initial public offering on the NASDAQOMX exchange on April 3.

Related News

Some patients surveyed preferred taking effervescent medicines. (Picture: Raymond Gilford/Flickr)

A bitter pill to swallow: young people dislike tablets more than old

Recipharm buys in Portiugal

Recipharm eyes Portugal and opthalmics with SEK1bn Lusomedicamenta buy

Topical medications: the EMA is revising its guidelines

EMA: clinical data may not be needed for topical comparisons

Pharmanest HQ in Sweden

Recipharm buys IUD-pain drug firm Pharmanest as part of consortium

Hospira announces two US recalls due to manufacturing, supplier issues

Hospira announces two US recalls due to manufacturing, supplier issues

New lollipop is a sucker for pain management

US FDA sued for alleged 'unlawful' detention of API batch

US FDA sued for alleged 'unlawful' detention of API batch destined for CMO

Endo Pharmaceuticals pain patch results painful

Related Products

See more related products